In the context of allergic diseases, current unmethylated CpG ODN adjuvants are designed to shift Th2-skewed allergic responses toward a Th1-biased profile to reduce allergies, but this immune activation may also increase TNF-α levels that have been associated with toxic shocks in mice [7,8]. The gene discussed is TNF; the disease is allergic disease.